News
6d
News-Medical.Net on MSNFAM111B identified as a key driver of glioma progression and therapeutic targetGliomas are among the deadliest brain tumors, with limited treatment options and poor survival rates. Scientists from China ...
Each time a cell divides, a small section of each chromosome's protective cap—the telomere—is worn away. Most cells use an ...
While surgery using 5-aminolevulinic acid improves total resection rates in high-grade glioma, the best outcomes are seen ...
Gliomas are among the deadliest brain tumors, with limited treatment options and poor survival rates. Scientists from China ...
The cells in a glioma look like healthy brain cells called glial cells. As a glioma grows, it forms a mass of cells called a tumor. The tumor can grow to press on brain or spinal cord tissue, ...
Gliomas are among the most aggressive brain tumors, with glioblastoma offering a median survival of 12 to 15 months. Despite advances in surgical, ...
Diffuse midline glioma (DMG), H3K27-altered, is a lethal pediatric high-grade tumor, lacking effective treatment options, primarily depending on clinical trials. Epigenetic agent-based ...
If you have an IDH-mutant glioma, the tumor cells release an IDH enzyme that doesn’t work as it should. The mutant enzyme produces D-2 hydroxyglutarate (D-2HG) — a molecule that encourages ...
Depiction of europium complexes changing structure upon interacting with a tumor cell. [Mengfei Wang, et al. Scientific Reports. January 22, 2024] Collaborating researchers led by a team at ...
In our 2019 paper, we tested an antiseizure medicine called perampanel that targets a receptor on glioma cells. It really nicely slowed glioma growth in mice. We can take FDA-approved medicines ...
These cells’ rhythms are a drumbeat that further amps up glioma growth. When the team physically destroyed these cells, or pharmacologically suppressed them, tumor development drastically slowed.
BCAS1 + cells in diffuse gliomas are morphologically different from BCAS1 + cells in healthy brain tissue. Credit: Oncotarget (2024). DOI: 10.18632/oncotarget.28553 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results